• 1
    Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for anxiety, depression, mania, and schizophrenia. Acta Psychiatr Scand 1986;73(Suppl. 326):136.
  • 2
    Lingjærde O, Ahlfors UG, Bech P, Denscher SJ, Elgen K. The UKU Side Effect Rating Scale. Acta Psychiatr Scand 1987;76(suppl. 334):7100.
  • 3
    Bech P, Ahlfors UG, Dencker SJ, Elgen K, Lingjærde O. UKU’s bivirkningsskala. Skala til registrering af uønskede virkninger af psykofarmaka. (UKU’s side effect scale for measuring unwanted effects of psychopharmacological drugs). Nord J Psychiatr 1986;40:147157.
  • 4
    Bech P, Olsen RL, Kjoller M, Rasmussen NK. Measuring well-being rather than absence of distress symptoms: a comparison of the SF-36 mental health subscale with the WHO-FIVE Well-Being Scale. Int J Meth Psychiatr Res 2003;12:8591.
  • 5
    Sisask M, Värnik A, Kolves K, Konstabel K, Wasserman D. Subjective psychological well-being (WHO-5) in assessment of the severity of suicide attempt. Nord J Psychiatr 2008;62:431435.
  • 6
    Bech P. Quality of life instruments in depression. Eur Psychiatry 1997;12:194198.
  • 7
    Bech P. 50 years with the Hamilton scales for anxiety and depression. Psychother Psychosom 2009;78:135142.
  • 8
    Martin-löft P. The notion of redundancy and its use as a qualitative measure of the discrepancy between a statistical hypothesis and a set of observational data. Scand J Statist 1974;1:318.
  • 9
    Montgomery SA, ÅSberg M. A new depression scale designed to be sensitive to change. Brit J Psychiat 1979;134:382389.
  • 10
    Spearman C. The abilities of man. New York: Macmillan, 1927.
  • 11
    Mckeown B, Thomas D. Q methodology. London: Sage Publications, 1988.
  • 12
    Bech P, Allerup P, Gram LF et al. The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981;63:290299.
  • 13
    Bech P, Allerup P, Reisby N. Assessment of symptom change from improvement curves on the Hamilton Depression Scales in trials with antidepressants. Psychopharmacology 1984;84:276281.
  • 14
    Rasch G. Probalistic models for some intelligence and attainment tests. Copenhagen: Danish Institute for Educational Research, 1960 (reprinted by University of Chicago Press, Chicago, 1980).
  • 15
    Bech P. Rating scales for psychopathology, health status and quality of life. Berlin: Springer, 1993.
  • 16
    Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799812.
  • 17
    Overall JE. The Brief Psychiatric Rating Scale in psychopharmacological research. In: PichotP, ed. Psychological measurements in psychopharmacology. Basel: Karger, 1974:6768.
  • 18
    Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Positive and Negative Syndrome Scale for Schizophrenia. Psychiatr Res 1988;23:99110.
  • 19
    Bech P, Larsen JK, Andersen J. The BPRS psychometric developments. Psychopharmacol Bull 1988;24:118121.
  • 20
    Andersen J, Larsen JK, Schultz V. The Brief Psychiatric Rating Scale. Dimensions of schizophrenia, reliability and construct validity. Psychopathology 1989;22:168176.
  • 21
    Hafkenscheid A. Psychometric evaluation of a standardized and expanded Brief Psychiatric Rating Scale. Acta Psychiatr Scand 1991;84:294300.
  • 22
    Hafkenscheid A. Reliability of a standardized and expanded Brief Psychiatric Rating Scale. Acta Psychiatr Scand 1993;86:16.
  • 23
    Bech P. The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: 20-year review of its use as an outcome measure. CNS Drugs 2002;16:4763.
  • 24
    Young RC, Biggs JT, Ziegler VE et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429435.
  • 25
    Bech P, Gex-Fabry M, Aubry J-M, Favre S, Bertschy G. Olazapine plasma level in relationship to antimanic effect in the acute therapy of manic states. Nord J Psychiatry 2006;60:181182.
  • 26
    Gjerris A, Bech P, Broen-Christensen C, Geisler A, Klysner R, Rafaelsen OJ. Haloperidol plasma levels in relation to antimanic effect. In: UsdinE, DahlS, GramLF, LingjærdeO, eds. Clinical pharmacology and psychiatry. London: MacMillan, 1980:227232.
  • 27
    Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am J Psychiatry 2000;157:463465.
  • 28
    Licht RW, Bysted M, Christensen H. Fixed-dosed risperidone in mania: an open experimental trial. Int Clin Psychopharmacol 2001;16:103110.
  • 29
    Overall JE. The dimensions of manifest depression. Psychiatr Res 1962;1:239245.
  • 30
    Bech P. P Pichot – a tribute to the European pharmacopsychologist on his 90th birthday. Eur Psychiatr Rev 2008;1:7680.
  • 31
    Feighner JP, Boyer WF, Meredith CH, Hendrickson GC. A placebo-controlled inpatient comparison of fluvoxamine maleate and impramine in major depression. Int Clin Psychopharmacol 1989;4:239244.
  • 32
    Politis AM, Papadimitriou GN, Theleritis CG, Psarros C, Soldatos CR. Combination therapy with amisulpiride and antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:12271230.
  • 33
    Norton KRW, Sireling LI, Bhat AV, Rao B, Paykel ES. A double blind comparison of fluvoxamine, imipramine and placebo in depressed patients. J Affect Dis 1984;7:297308.
  • 34
    Bech P, Gram LF, Dein E. Qualitative rating of depressive states. Acta Psychiatr Scand 1975;51:161170.
  • 35
    Lunn V. Afsind (Insanity). Copenhagen: Gyldendal, 1987.
  • 36
    Lehman H. Psychopharmacotherapy. In: HealyD, ed. The psychopharmacologists I. London: Chapman & Hall, 1996:159186.
  • 37
    Santen G, Gomeni R, Danhof M, Pasqua OD. Sensitivity of the individual items of the Hamilton Depression Scale to response and its consequence for the assessment of efficacy. Psychiatr Res 2008;42:1001009.
  • 38
    Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando, FL: Academic Press, 1985.
  • 39
    Bech P, Cialdella P, Haugh M et al. A meta-analysis of randomised controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000;176:421428.
  • 40
    Entsuah R, Shaffer M, Zhang J. A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. J Psychiatr Res 2002;36:437448.
  • 41
    Bech P, Tanghøj P, Andersen HF, Overø K. Citalopram dose–response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo. Psychopharmacology 2002;163:2025.
  • 42
    Bech P, Tanghøj P, Cialdella P, Friis Andersen H, Pedersen AG. Escitalopram dose–response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004;7:283290.
  • 43
    Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 2001;4:337345.
  • 44
    Pinder RM, Zivkov M. On demonstrating the correct dose for new antidepressants. In: BalantLP, BenitezJ, DahlSG, GramLF, PinderRM, PotterWZ, eds. Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs. Brussels: European Commission, 1998:3142.
  • 45
    Schweizer E, Rickels K. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J Clin Psychiatry 1997;58(Suppl. 11):3038.
  • 46
    Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trezodone and diazepam. Arch Gen Psychiatr 1993;50:884895.
  • 47
    Meoni P, Salinas E, Brault Y, Hachet D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry 2001;62:888893.
  • 48
    Stahl SM, Ahmed S, Haudiquet V. Analysis of the rate of improvement of specific psychic and somatic symptoms of generalized anxiety disorder during long-term treatment with Venlafaxine ER. CNS Spectr 2007;12:703711.
  • 49
    Bech P. Dose–response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 2007;40:163168.
  • 50
    Bech P. Quality of life in the psychiatric patient. London: Mosby-Wolfe, 1998.
  • 51
    Sartorius N. Cross-cultural comparisons of data about quality of life. In: AaronsonNK, BeckmannJ, eds. The quality of life in cancer patients. New York: Raven Press, 1987:1924.
  • 52
    Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: WengerNK, MattsonME, FurbergCD, ElinsonJ, eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984:184188.
  • 53
    Ware JE. The SF-36 health survey. In: SpilkerB, ed. Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Philadelphia, PA: Lippincott-Raven, 1996:337345.
  • 54
    Bech P, Lunde M, Bech-Andersen G, Lindberg L, Martiny K. Psychiatric outcome studies (POS): does treatment help the patients? A Popperian approach to research in clinical psychiatry. Nord J Psychiatry 2007;61(suppl. 46):480.
  • 55
    Bech P. Social functioning. Should it become an endpoint in trials of antidepressants? CNS Drugs 2005;19:313324.
  • 56
    Feinstein AR. Clinimetrics. New Haven, CT: Yale University Press, 1987.
  • 57
    Magee B, Milligan M. On blindness. Oxford: Oxford University Press, 1995.
  • 58
    Brunswik E. Perception and the representative design of psychological experiments. Los Angeles, CA: University of California Press, 1956.
  • 59
    Bech P. Fifty years with the Hamilton scales for anxiety and depression. Psychother Psychosom 2009;78:202211.
  • 60
    Fleck MPA, Poirter-Littre MF, Guilfi G-D. Factorial structure of the 17-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1995;92:168176.
  • 61
    Uher R, Farmer A, Maier W. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008;38:289300.
  • 62
    Hamilton M. The role of rating scales in psychiatry. Psychol Med 1976;6:347349.
  • 63
    Pichot P. Psychological measurements in psychopharmacology. Basel: Karger, 1974.
  • 64
    Paykel ES. The clinical interview for depression. In: SartoriusN, BanTA, eds. Assessment of depression. Berlin: Springer, 1986:304315.
  • 65
    Pichot P. A century of psychiatry. Paris: Editions Roger Dacosta, 1983.
  • 66
    Ban T. Prolegomenon to clinical prerequisite: psychopharmacology and the classification of mental disorders. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:527580.
  • 67
    Engle RL. Medical diagnosis: past, present and future II. Philosophical foundations and historical development of our concepts of health, disease and diagnosis. Arch Intern Med 1963;112:520529.
  • 68
    Klerman GL. The contemporary American scene: diagnosis and classification of mental disorders, alcoholism and drug abuse. In: SaroriusN, JablenskyA, RegierDA, BurkeJD, HirshfeltRMA, eds. Sources and tradition of classification in psychiatry. Bern: Hogrefe & Huber, 1990:93137.
  • 69
    Spitzer RL. A manual for diagnosis and statistics. In: HealyD, ed. The psychopharmacologist’s III. London: Arnold, 2000:415430.
  • 70
    Leon AC, Shear MK, Portea L, Klerman GL. Effect size as a measure of symptom-specific drug change in clinical trials. Psychopharmacol Bull 1993;29:163167.
  • 71
    Power M. Development of a common instrument for quality of life. In: NosikovA, GudexC, eds. EUROHIS Developing common instruments for health surveys. Amsterdam: IOS Press, 2003:145163.